Medicines and Healthcare products Regulatory Agency

The Medicines and Healthcare products Regulatory Agency (MHRA) is a UK government agency responsible for ensuring that medicines, medical devices, and blood components for transfusion meet applicable standards of safety, quality, and efficacy.

Communication Overview

Total releases

Number of press releases published by this department during the last 12 months, based on publicly available announcements.

588

Avg per month

Average number of press releases published per calendar month over the last 12 months. This smooths short-term fluctuations in publishing activity.

12.3

Avg word count

Average length of published press releases, measured in words. Calculated only for months where content was published.

871

Avg readability

Average Flesch Reading Ease score across all published press releases. Higher values indicate plainer English. Scores are indicative only and vary by subject matter.

26.8

Friday PM releases

Percentage of press releases published after 3pm on Fridays, relative to the department’s total output during the period.

3.8%

Single-release items

Estimated proportion of announcements published once, without a closely related follow-up release during the same period. This is based on similarity of titles and timing.

100%

Metrics are descriptive only and indicate publication patterns rather than intent or impact.

Releases per month

Based on publicly published press releases (last 12 months)

830 articles

Showing 1-30

Precautionary?recall of antidepressant medication due to manufacturing error

Tuesday, 28 April 2026

The MHRA?has?advised healthcare professionals to?stop supplying the affected?batch of Sertraline 100mg?and?return all remaining stock to their supplie...

Read More → press_release

MHRA delivers its targets to increase access to medicines and reinforce UK position as a global destination for life sciences

Tuesday, 28 April 2026

The MHRA continues to speed up access to medicines for patients, increase efficiency of regulation and help to attract innovation and investment in th...

Read More → press_release

Launch of clinical trial reforms

Monday, 27 April 2026

Patients in the UK to get access to new treatments faster and still safely under new clinical trial regulations coming into force on 28 April 2026....

Read More → press_release

Precautionary recall of medication used for pain and inflammation?due to incomplete patient information

Thursday, 23 April 2026

Specific batches of Napralief 250mg Gastro?Resistant Tablets are being recalled because important safety and dosage information is missing from both t...

Read More → press_release

Enflonsia (clesrovimab cfor) approved to prevent RSV in newborns and infants

Wednesday, 22 April 2026

As with any medicine, the MHRA will keep the safety and effectiveness of Enflonsia under close review....

Read More → press_release

Precautionary recall of blood pressure medication after manufacturing error

Monday, 20 April 2026

The MHRA?has?advised pharmacy and healthcare professionals to stop supplying the impacted batch and?return all remaining stock to their suppliers....

Read More → press_release

How to seize the growing opportunities of AI and technology ahead

Wednesday, 15 April 2026

By Dame Jennifer Dixon...

Read More → news_story

Single dose 7.2mg semaglutide (Wegovy) pen approved to treat adult patients with obesity

Tuesday, 14 April 2026

As with any medicine, the MHRA will keep the safety and effectiveness of Wegovy under close review....

Read More → news_story

MHRA and eBay working in partnership to safeguard public health

Monday, 13 April 2026

MHRA and eBay partnership removes 215 listings of potentially dangerous medicines from the eBay platform highlighting the benefits of private/public w...

Read More → press_release

Access Consortium Promise Pilot Pathway

Friday, 10 April 2026

New Access Work-Sharing Pathway for Priority Procedures....

Read More → news_story

MHRA approves olezarsen (Tryngolza) for the treatment of familial chylomicronemia syndrome

Friday, 10 April 2026

MHRA approves olezarsen (Tryngolza) for the treatment of familial chylomicronemia syndrome ...

Read More → press_release

MHRA expands AI Airlock programme with a £3.6 million funding boost over three years

Wednesday, 08 April 2026

The MHRA continues to be at the forefront of innovation and secures multi-year funding to expand its pioneering AI Airlock programme....

Read More → press_release

Access Consortium sets 2026 priorities to accelerate work sharing and improve patient access to innovative medicines

Tuesday, 07 April 2026

The MHRA-led Access Consortium 2026 action plan will deepen collaboration, streamline work sharing, and speed up access to safe, high-quality medicine...

Read More → news_story

UK and US deepen regulatory cooperation on medical devices, building on wider pharmaceutical partnership

Thursday, 02 April 2026

The Medicines and Healthcare products Regulatory Agency and the US Food and Drug Administration are strengthening cooperation on medical device regula...

Read More → press_release

Sevabertinib approved to treat adults with HER2 positive lung cancer that has spread or cannot be removed by surgery

Thursday, 02 April 2026

As with any medicine, the MHRA will keep the safety and effectiveness of sevabertinib under close review. ...

Read More → press_release

Shaping the Future of Healthcare Through Global Regulatory Innovation

Wednesday, 25 March 2026

Emerging technologies like AI and advanced therapies are transforming healthcare, and through international collaboration with partners such as Singap...

Read More → news_story

MHRA Chief Executive update to MHRA staff on the Pathways clinical trial

Tuesday, 24 March 2026

As with all clinical trials, the MHRA’s top priority is the safety and wellbeing of the trial participants....

Read More → news_story

MHRA action boosts drive to phase out animal testing

Tuesday, 24 March 2026

Medicines and Healthcare products Regulatory Agency (MHRA) takes decisive action to phase out animal testing by helping developers to make greater use...

Read More → press_release

Precautionary recall of Hibiwash due to microbial contamination

Monday, 23 March 2026

As a precautionary measure, Mölnlycke Health Care is recalling three batches of Hibiwash, an antimicrobial wash, due to microbial contamination at the...

Read More → press_release

Patients to get new medicines up to six months sooner under new joint MHRA NICE approval process

Tuesday, 17 March 2026

New pathway set to synchronise licensing and value assessment decisions...

Read More → press_release

The £1.4bn opportunity: How reclassification can transform healthcare, improve access to medicines and enable growth

Thursday, 12 March 2026

Expanding medicine reclassification could improve access to treatments, empower self-care, and reduce pressure on NHS services....

Read More → news_story

MHRA approves deuruxolitinib (Leqselvi) to treat severe alopecia areata in adults

Thursday, 12 March 2026

As with any medicine, the MHRA will keep the safety and effectiveness of deuruxolitinib under close review....

Read More → press_release

Global impact of UK health data resource highlighted in newly published paper

Tuesday, 10 March 2026

New analysis shows Clinical Practice Research Datalink has supported groundbreaking medical research across 29 countries with close to 3,800 published...

Read More → press_release

Precautionary recall of blood pressure medication after packaging error

Friday, 06 March 2026

The MHRA?has advised pharmacy and healthcare professionals to return all remaining stock to their suppliers...

Read More → press_release

Man jailed for ten years for convictions including selling prescription only medicines worth more than £3.7million

Tuesday, 03 March 2026

A man who unlawfully supplied Class B and Class C controlled drugs and a range of unauthorised medicines has been sentenced at Stoke-on-Trent Crown Co...

Read More → press_release

MHRA statement on Pathways clinical trial

Friday, 27 February 2026

As with all clinical trials, the MHRA’s top priority is the safety and wellbeing of the trial participants....

Read More → news_story

MHRA patient safety essay competition 2025

Wednesday, 25 February 2026

The MHRA invited the next generation of doctors to explore how genetics could improve prescribing and patient safety in the UK....

Read More → press_release

MHRA disrupts second manufacturing facility suspected to be involved in the manufacture of illegal weight loss medicines in latest blow to criminal network

Wednesday, 25 February 2026

Officers from the MHRA's Criminal Enforcement Unit (CEU) have raided two separate premises as part of an ongoing investigation into an organised crimi...

Read More → press_release